Vivoryon Therapeutics N.V.
VVY.AS · AMS
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €0 | -€3,620 | €0 | €10,764 |
| % Growth | 100% | – | -100% | – |
| Cost of Goods Sold | €147 | -€525 | €161 | €1,734 |
| Gross Profit | -€147 | -€3,095 | -€161 | €9,030 |
| % Margin | – | 85.5% | – | 83.9% |
| R&D Expenses | €14,058 | €17,637 | €20,224 | €17,452 |
| G&A Expenses | €6,900 | €3,272 | €8,905 | €5 |
| SG&A Expenses | €6,756 | €3,272 | €8,747 | €4,384 |
| Sales & Mktg Exp. | €0 | €0 | €3 | €4,379 |
| Other Operating Expenses | €0 | €4,833 | €0 | €0 |
| Operating Expenses | €20,814 | €25,742 | €28,971 | €21,836 |
| Operating Income | -€20,961 | -€28,837 | -€29,132 | -€12,806 |
| % Margin | – | 796.6% | – | -119% |
| Other Income/Exp. Net | €393 | €261 | €777 | €575 |
| Pre-Tax Income | -€20,568 | -€28,576 | -€28,355 | -€12,223 |
| Tax Expense | €0 | -€234 | -€199 | €432 |
| Net Income | -€20,568 | -€28,342 | -€28,156 | -€12,655 |
| % Margin | – | 782.9% | – | -117.6% |
| EPS | -0.79 | -1.12 | -1.28 | -0.63 |
| % Growth | 29.5% | 12.5% | -103.2% | – |
| EPS Diluted | -0.79 | -1.12 | -1.28 | -0.63 |
| Weighted Avg Shares Out | 26,035 | 25,242 | 22,020 | 20,000 |
| Weighted Avg Shares Out Dil | 26,035 | 25,242 | 22,020 | 20,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | €482 | €478 | €42 | €21 |
| Interest Expense | €86 | €56 | €24 | €24 |
| Depreciation & Amortization | €147 | €167 | €161 | €165 |
| EBITDA | -€20,335 | -€28,353 | -€28,170 | -€12,034 |
| % Margin | – | 783.2% | – | -111.8% |